KROS241220P20000
- 2.20
- +0.20+10.00%
Keros Therapeutics Newsroom
Keros Therapeutics Is Maintained at Sector Outperform by Scotiabank
Keros Therapeutics Price Target Cut to $44.00/Share From $77.00 by Scotiabank
Jefferies Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $44
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $47 to $84
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Lowers Price Target to $47
Keros Therapeutics Cut to Market Perform From Outperform by William Blair
Keros Therapeutics Analyst Ratings
Keros Therapeutics Is Maintained at Overweight by Wells Fargo
Keros Therapeutics Analyst Ratings
Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Raises Target Price to $111
Wells Fargo Sticks to Its Buy Rating for Keros Therapeutics (KROS)
Wedbush Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $84
Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $105
Oppenheimer Keeps Their Buy Rating on Keros Therapeutics (KROS)
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Incyte (INCY) and Prenetics Group (PRE)
Strategic Partnership and Financial Strength Bolster Keros Therapeutics' Buy Rating
Keros Therapeutics Analyst Ratings
Wedbush Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $84